PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).

	PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
	Zeng, Jian ; Wang, Guoqiang ; Yan, Zhengqing ; Zheng, Hao ; Li, Jianqiang ; Tao, Feng
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2020-05-20
卷号	38
ISSN号	0732-183X
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000560368305104
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/120547]
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China 2.3D Med Inc, Med Dept, Shanghai, Peoples R China 3.Wen Zhou Med Univ, Lishui Peoples Hosp, Dept Resp Med, Affiliated Hosp 6, Lishui, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 5.Jiaxing Univ, Dept Resp Med, Affiliated Hosp, Jiaxing, Peoples R China
推荐引用方式 GB/T 7714	Zeng, Jian,Wang, Guoqiang,Yan, Zhengqing,et al. PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).[J]. JOURNAL OF CLINICAL ONCOLOGY,2020,38.
APA	Zeng, Jian,Wang, Guoqiang,Yan, Zhengqing,Zheng, Hao,Li, Jianqiang,&Tao, Feng.(2020).PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC)..JOURNAL OF CLINICAL ONCOLOGY,38.
MLA	Zeng, Jian,et al."PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).".JOURNAL OF CLINICAL ONCOLOGY 38(2020).